Key result
Evidence-based treatments for heart failure necessitate polypharmacy, utilizing combinations of ACE inhibitors, beta-blockers, and other agents to optimally reduce morbidity and mortality.
This review highlights the necessity of polypharmacy in heart failure management to address complex neurohormonal pathways and improve patient survival and morbidity.
Supports guideline-directed polypharmacy in HF; leaves open optimal sequencing and adherence strategies.
The concept of heart failure has undergone several paradigm shifts in the past few decades. Therapeutic targets directed at the heart pump have shifted to circulatory haemodynamics to the current neurohormonal model. Consequently, therapeutic modalities have similarly evolved alongside clinical trials. Successive trials have tested newer drugs in addition to established therapies, resulting in evidence-based treatments necessitating polypharmacy. Optimal heart failure therapy has therefore become increasingly complex. It is only after understanding the precise modes of drug action, as well as the relevance of the design of clinical trials, will physicians hopefully be able to tailor the medical therapy optimally towards the individual patient with heart failure.
No takes yet. Share an insight, caveat, or question.
BWK Kwok (2004) conducted a review in Heart Failure. Medical therapy (polypharmacy) was evaluated. Evidence-based treatments for heart failure necessitate polypharmacy, utilizing combinations of ACE inhibitors, beta-blockers, and other agents to optimally reduce morbidity and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: